tiprankstipranks
Trending News
More News >
Inovio Pharmaceuticals (INO)
NASDAQ:INO
Advertisement

Inovio Pharmaceuticals (INO) Stock Statistics & Valuation Metrics

Compare
5,903 Followers

Total Valuation

Inovio Pharmaceuticals has a market cap or net worth of $108.41M. The enterprise value is $42.13M.
Market Cap$108.41M
Enterprise Value$42.13M

Share Statistics

Inovio Pharmaceuticals has 53,142,662 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding53,142,662
Owned by Insiders0.54%
Owned by Institutions4.58%

Financial Efficiency

Inovio Pharmaceuticals’s return on equity (ROE) is -1.57 and return on invested capital (ROIC) is -0.13%.
Return on Equity (ROE)-1.57
Return on Assets (ROA)-0.95
Return on Invested Capital (ROIC)-0.13%
Return on Capital Employed (ROCE)-1.44
Revenue Per Employee1.63K
Profits Per Employee-800.40K
Employee Count134
Asset Turnover<0.01
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Inovio Pharmaceuticals is ―. Inovio Pharmaceuticals’s PEG ratio is ―.
PE Ratio
PS Ratio
PB Ratio
Price to Fair Value0.73
Price to FCF
Price to Operating Cash Flow>-0.01
PEG Ratio

Income Statement

In the last 12 months, Inovio Pharmaceuticals had revenue of 217.76K and earned -107.25M in profits. Earnings per share was -3.95.
Revenue217.76K
Gross Profit-2.91M
Operating Income-112.40M
Pretax Income-107.25B
Net Income-107.25M
EBITDA-103.95M
Earnings Per Share (EPS)-3.95

Cash Flow

In the last 12 months, operating cash flow was -132.06B and capital expenditures 487.83K, giving a free cash flow of -132.06B billion.
Operating Cash Flow-132.06B
Free Cash Flow-132.06B
Free Cash Flow per Share-2.49K

Dividends & Yields

Inovio Pharmaceuticals pays an annual dividend of $0.069, resulting in a dividend yield of ―
Dividend Per Share$0.069
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.69
52-Week Price Change-66.39%
50-Day Moving Average1.68
200-Day Moving Average2.17
Relative Strength Index (RSI)79.76
Average Volume (3m)1.79M

Important Dates

Inovio Pharmaceuticals upcoming earnings date is Nov 11, 2025, TBA (Confirmed).
Last Earnings DateAug 12, 2025
Next Earnings DateNov 11, 2025
Ex-Dividend DateSep 28, 2017

Financial Position

Inovio Pharmaceuticals as a current ratio of 2.77, with Debt / Equity ratio of 37.36%
Current Ratio2.77
Quick Ratio2.77
Debt to Market Cap0.05
Net Debt to EBITDA0.52
Interest Coverage Ratio-632.05

Taxes

In the past 12 months, Inovio Pharmaceuticals has paid -107.15B in taxes.
Income Tax-107.15B
Effective Tax Rate1.00

Enterprise Valuation

Inovio Pharmaceuticals EV to EBITDA ratio is 0.04, with an EV/FCF ratio of 0.04.
EV to Sales-19.49
EV to EBITDA0.04
EV to Free Cash Flow0.04
EV to Operating Cash Flow0.04

Balance Sheet

Inovio Pharmaceuticals has $47.55M in cash and marketable securities with $10.66M in debt, giving a net cash position of -$36.89M billion.
Cash & Marketable Securities$47.55M
Total Debt$10.66M
Net Cash-$36.89M
Net Cash Per Share-$0.69
Tangible Book Value Per Share$2.52

Margins

Gross margin is -745.52%, with operating margin of -51616.91%, and net profit margin of -49254.27%.
Gross Margin-745.52%
Operating Margin-51616.91%
Pretax Margin-49254269.00%
Net Profit Margin-49254.27%
EBITDA Margin-47735.19%
EBIT Margin-49172.60%

Analyst Forecast

The average price target for Inovio Pharmaceuticals is $6.96, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.96
Price Target Upside182.93% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast-69.19%
EPS Growth Forecast48.94%

Scores

Smart Score5
AI Score51
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis